Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents

Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2000, Pages 1550-1562

  Wells, Geoffrey ^a   Seaton, Angela ^a   Steven, Malcolm F G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 IODO 4 PHENOXYPHENYL) 2 (PYRIDIN 2 YL)PROPENENITRILE; 3 (4 HYDROXY 3 METHOXYPHENYL) 2 (2 PYRIDYL)PROPENITRILE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH STIMULATION; HUMAN; HUMAN CELL; OXIDATION; STOICHIOMETRY;

ACETATES; ANTINEOPLASTIC AGENTS; BENZENE DERIVATIVES; BIPHENYL COMPOUNDS; CELL DIVISION; CELL LINE; ENZYME INHIBITORS; ESTROGENS; GROWTH SUBSTANCES; HUMANS; INDICATORS AND REAGENTS; IODOBENZENES; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0034692165     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990947f     Document Type: Article

References (53)

1. Julino, M.; Lowe, P. R.; Stevens, M. F. G. Structural studies on bioactive compounds. Part 31. Interaction of 9-azidoacridine and 1-morpholinocyclohexene: formation, decomposition and rearrangement of the intermediate 1,2,3-triazoline. J. Chem. Res. (S) 2000, 74-75.
2. Hunter, T.; Cooper, J. A. Protein tyrosine kinases. Annu. Rev. Biochem. 1985, 54, 897-930. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212. Fantl, W. J.; Johnson, D. E.; Williams, L. T. Signaling by receptor tyrosine kinases. Annu. Rev. Biochem. 1993, 62, 453-481.
3. Hunter, T.; Cooper, J. A. Protein tyrosine kinases. Annu. Rev. Biochem. 1985, 54, 897-930. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212. Fantl, W. J.; Johnson, D. E.; Williams, L. T. Signaling by receptor tyrosine kinases. Annu. Rev. Biochem. 1993, 62, 453-481.
4. Hunter, T.; Cooper, J. A. Protein tyrosine kinases. Annu. Rev. Biochem. 1985, 54, 897-930. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212. Fantl, W. J.; Johnson, D. E.; Williams, L. T. Signaling by receptor tyrosine kinases. Annu. Rev. Biochem. 1993, 62, 453-481.
5. Levitzki, A.; Gazit, A. Tyrosine kinase inhibition - an approach to drug development. Science 1994, 267, 1782-1788.
6. Chang, C. J.; Geahlen, R. L. Protein tyrosine kinase inhibition - mechanism based discovery of antitumour agents. J. Nat. Prod. 1992, 55, 1529-1560.
7. Koenders, P. G.; Beex, L. V. A. M.; Geurts-Moespot, A.; Heuvel, J. J. T. M.; Kienhuis, C. B. M.; Benraad, T. J. Epidermal growth factor receptor negative tumours are predominantly confined to the subgroup of estradiol receptor positive human primary breast cancer cells. Cancer Res. 1991, 51, 4544-4548.
8. van Agthoven, T.; van Agthoven, T. L. A.; Portengen, H.; Foekens, J. A.; Dorssens, C. J. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res. 1992, 52, 5082-5088.
9. Bartlett, J. M. S.; Langdon, S. P.; Simpson, B. J. B.; Stewart, M.; Katsaros, D.; Sismondi, P.; Love, S.; Scott, W. N.; Williams, A. R. W.; Lessells, A. M.; Macleod, K. G.; Smythe, J. F.; Miller, W. R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 1996, 73, 301-306.
10. Fry, D. W.; Kraker, A. J.; McMicheal, A.; Ambrose, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095. Denny, W. A.; Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Kraker, A. J. Structure activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin. Exp. Pharmacol. Physiol. 1996, 23, 424-427.
11. Fry, D. W.; Kraker, A. J.; McMicheal, A.; Ambrose, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095. Denny, W. A.; Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Kraker, A. J. Structure activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin. Exp. Pharmacol. Physiol. 1996, 23, 424-427.
12. Graziani, Y.; Chayoth, R.; Larny, N.; Feldman, B.; Levy, J. Regulation of protein kinase activity by quercetin in Erlich ascites tumour cells. Biochim. Biophys. Acta 1981, 714, 4121-4150.
13. Bridges, A. J. The epidermal growth factor receptor family of tyrosine kinases and cancer. Can an atypical exemplar be a sound therapeutic target? Curr. Med. Chem. 1996, 3, 167-194. Chang, C. J.; Geahlen, R. L. Protein tyrosine kinase inhibition - mechanism based discovery of antitumour agents. J. Nat. Prod. 1992, 55, 1529-1560.
14. Bridges, A. J. The epidermal growth factor receptor family of tyrosine kinases and cancer. Can an atypical exemplar be a sound therapeutic target? Curr. Med. Chem. 1996, 3, 167-194. Chang, C. J.; Geahlen, R. L. Protein tyrosine kinase inhibition - mechanism based discovery of antitumour agents. J. Nat. Prod. 1992, 55, 1529-1560.
15. Hsu, C.-Y.; Jacoski, M. V.; Maguire, M. P.; Spada, A. P.; Zilberstein, A. Inhibition kinetics and selectivity of the tyrosine kinase inhibitor erbstatin and a pyridone based analogue. Biochem. Pharmacol. 1992, 43, 2471-2477.
16. Gazit, A.; Yaish, P.; Gilon, C.; Levitzki, A. Tyrphostins I. Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 1989, 32, 2344-2352. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P.; Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins 2: Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB2/neu tyrosine kinases. J. Med. Chem. 1991, 34, 1896-1907.
17. Gazit, A.; Yaish, P.; Gilon, C.; Levitzki, A. Tyrphostins I. Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 1989, 32, 2344-2352. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P.; Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins 2: Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB2/neu tyrosine kinases. J. Med. Chem. 1991, 34, 1896-1907.
18. Osherov, N.; Gazit, A.; Gilon, C.; Levitzki, A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem. 1993, 268, 11134-11142.
19. Umezawa, K.; Imoto, M. Use of erbstatin as protein tyrosine kinase inhibitor. Methods Enzymol. 1991, 201, 379-385.
20. Ramdas, L.; McMurray, J. S.; Budde, R. J. A. The degree of inhibition of protein tyrosine kinase activity by Tyrphostin 23 and 25 is related to their instability. Cancer Res. 1994, 54, 867-869.
21. Faaland, C. A.; Mermelstein, F. H.; Hayastin, J.; Laskin, J. D. Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF) stimulated EGF receptor tyrosine kinase activity. Mol. Cell Biol. 1991, 11, 2697-2703.
22. Reddy, K. B.; Mangold, G. L.; Tandon, A. K.; Yoneda, T.; Mundy, G. R.; Zilberstein, A. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992, 52, 3631-3641.
23. For examples, see: Szantay, C.; Blasko, G.; Baczai-Beke, M.; Pecky, P.; Dornyei, G. Studies aimed at the synthesis of morphine II. Tetrahedron Lett. 1980, 21, 3509-3512. Pelter, A.; Ward, P. S.; Abd-El-Ghani, A. Preparation of dibenzocyclooctadiene lignans and spirodienones by hypervalent iodine oxidation of phenolic dibenzylbutyrolactones. J. Chem. Soc., Perkin Trans. 1 1992, 2249-2251. Kita, Y.; Takada, T.; Gyoten, M.; Tohma, H.; Zenk, M. H.; Eichhorn, J. An oxidative intramolecular phenolic coupling reaction for the synthesis of amaryllidaceae alkaloids using a hypervalent iodine (III) reagent. J. Org. Chem. 1996, 61, 5857-5864. Chu, C. S.; Liao, C. C.; Rao, P. D. A formal synthesis of (±)reserpine from methyl vanillate. J. Chem. Soc., Chem. Commun. 1996, 1537-1538.
24. For examples, see: Szantay, C.; Blasko, G.; Baczai-Beke, M.; Pecky, P.; Dornyei, G. Studies aimed at the synthesis of morphine II. Tetrahedron Lett. 1980, 21, 3509-3512. Pelter, A.; Ward, P. S.; Abd-El-Ghani, A. Preparation of dibenzocyclooctadiene lignans and spirodienones by hypervalent iodine oxidation of phenolic dibenzylbutyrolactones. J. Chem. Soc., Perkin Trans. 1 1992, 2249-2251. Kita, Y.; Takada, T.; Gyoten, M.; Tohma, H.; Zenk, M. H.; Eichhorn, J. An oxidative intramolecular phenolic coupling reaction for the synthesis of amaryllidaceae alkaloids using a hypervalent iodine (III) reagent. J. Org. Chem. 1996, 61, 5857-5864. Chu, C. S.; Liao, C. C.; Rao, P. D. A formal synthesis of (±)reserpine from methyl vanillate. J. Chem. Soc., Chem. Commun. 1996, 1537-1538.
25. For examples, see: Szantay, C.; Blasko, G.; Baczai-Beke, M.; Pecky, P.; Dornyei, G. Studies aimed at the synthesis of morphine II. Tetrahedron Lett. 1980, 21, 3509-3512. Pelter, A.; Ward, P. S.; Abd-El-Ghani, A. Preparation of dibenzocyclooctadiene lignans and spirodienones by hypervalent iodine oxidation of phenolic dibenzylbutyrolactones. J. Chem. Soc., Perkin Trans. 1 1992, 2249-2251. Kita, Y.; Takada, T.; Gyoten, M.; Tohma, H.; Zenk, M. H.; Eichhorn, J. An oxidative intramolecular phenolic coupling reaction for the synthesis of amaryllidaceae alkaloids using a hypervalent iodine (III) reagent. J. Org. Chem. 1996, 61, 5857-5864. Chu, C. S.; Liao, C. C.; Rao, P. D. A formal synthesis of (±)reserpine from methyl vanillate. J. Chem. Soc., Chem. Commun. 1996, 1537-1538.
26. For examples, see: Szantay, C.; Blasko, G.; Baczai-Beke, M.; Pecky, P.; Dornyei, G. Studies aimed at the synthesis of morphine II. Tetrahedron Lett. 1980, 21, 3509-3512. Pelter, A.; Ward, P. S.; Abd-El-Ghani, A. Preparation of dibenzocyclooctadiene lignans and spirodienones by hypervalent iodine oxidation of phenolic dibenzylbutyrolactones. J. Chem. Soc., Perkin Trans. 1 1992, 2249-2251. Kita, Y.; Takada, T.; Gyoten, M.; Tohma, H.; Zenk, M. H.; Eichhorn, J. An oxidative intramolecular phenolic coupling reaction for the synthesis of amaryllidaceae alkaloids using a hypervalent iodine (III) reagent. J. Org. Chem. 1996, 61, 5857-5864. Chu, C. S.; Liao, C. C.; Rao, P. D. A formal synthesis of (±)reserpine from methyl vanillate. J. Chem. Soc., Chem. Commun. 1996, 1537-1538.
27. Kurti, L.; Herczegh, P.; Visy, J.; Simonyi, M.; Antus, S.; Pelter, A. New insights into the mechanism of phenolic oxidation with phenyliodonium (III) reagents. J. Chem. Soc., Perkin Trans. 1 1999, 379-380.
28. Koser, G. F. Hypervalent halogen compounds. In The Chemistry of Functional Groups, Supplement D; Patai, S., Rappoport, Z., Eds.; John Wiley and Sons Ltd.: London, 1983; pp 721-811. Varvoglis, A. Aryliodine(III)dicarboxylates. Chem. Soc. Rev. 1981, 10, 377-407. Varvoglis, A. [Bis(acyloxy)iodo]arenes. In The Organic Chemistry of Polycoordinated Iodine; Varvoglis, A., Ed.; VCH Publishers Inc.: New York, 1992; pp 55-129. Pelter, A.; Elgendy, S. M. A. Phenolic oxidations with phenyliodonium diacetate. J. Chem. Soc., Perkin Trans. 1 1993, 1891-1896. Varvoglis, A.; Spyroudis, S. Hypervalent iodine chemistry: 25 years of development at the university of Thessaloniki. Synlett 1998, 221-232.
29. Koser, G. F. Hypervalent halogen compounds. In The Chemistry of Functional Groups, Supplement D; Patai, S., Rappoport, Z., Eds.; John Wiley and Sons Ltd.: London, 1983; pp 721-811. Varvoglis, A. Aryliodine(III)dicarboxylates. Chem. Soc. Rev. 1981, 10, 377-407. Varvoglis, A. [Bis(acyloxy)iodo]arenes. In The Organic Chemistry of Polycoordinated Iodine; Varvoglis, A., Ed.; VCH Publishers Inc.: New York, 1992; pp 55-129. Pelter, A.; Elgendy, S. M. A. Phenolic oxidations with phenyliodonium diacetate. J. Chem. Soc., Perkin Trans. 1 1993, 1891-1896. Varvoglis, A.; Spyroudis, S. Hypervalent iodine chemistry: 25 years of development at the university of Thessaloniki. Synlett 1998, 221-232.
30. Koser, G. F. Hypervalent halogen compounds. In The Chemistry of Functional Groups, Supplement D; Patai, S., Rappoport, Z., Eds.; John Wiley and Sons Ltd.: London, 1983; pp 721-811. Varvoglis, A. Aryliodine(III)dicarboxylates. Chem. Soc. Rev. 1981, 10, 377-407. Varvoglis, A. [Bis(acyloxy)iodo]arenes. In The Organic Chemistry of Polycoordinated Iodine; Varvoglis, A., Ed.; VCH Publishers Inc.: New York, 1992; pp 55-129. Pelter, A.; Elgendy, S. M. A. Phenolic oxidations with phenyliodonium diacetate. J. Chem. Soc., Perkin Trans. 1 1993, 1891-1896. Varvoglis, A.; Spyroudis, S. Hypervalent iodine chemistry: 25 years of development at the university of Thessaloniki. Synlett 1998, 221-232.
31. Koser, G. F. Hypervalent halogen compounds. In The Chemistry of Functional Groups, Supplement D; Patai, S., Rappoport, Z., Eds.; John Wiley and Sons Ltd.: London, 1983; pp 721-811. Varvoglis, A. Aryliodine(III)dicarboxylates. Chem. Soc. Rev. 1981, 10, 377-407. Varvoglis, A. [Bis(acyloxy)iodo]arenes. In The Organic Chemistry of Polycoordinated Iodine; Varvoglis, A., Ed.; VCH Publishers Inc.: New York, 1992; pp 55-129. Pelter, A.; Elgendy, S. M. A. Phenolic oxidations with phenyliodonium diacetate. J. Chem. Soc., Perkin Trans. 1 1993, 1891-1896. Varvoglis, A.; Spyroudis, S. Hypervalent iodine chemistry: 25 years of development at the university of Thessaloniki. Synlett 1998, 221-232.
32. Koser, G. F. Hypervalent halogen compounds. In The Chemistry of Functional Groups, Supplement D; Patai, S., Rappoport, Z., Eds.; John Wiley and Sons Ltd.: London, 1983; pp 721-811. Varvoglis, A. Aryliodine(III)dicarboxylates. Chem. Soc. Rev. 1981, 10, 377-407. Varvoglis, A. [Bis(acyloxy)iodo]arenes. In The Organic Chemistry of Polycoordinated Iodine; Varvoglis, A., Ed.; VCH Publishers Inc.: New York, 1992; pp 55-129. Pelter, A.; Elgendy, S. M. A. Phenolic oxidations with phenyliodonium diacetate. J. Chem. Soc., Perkin Trans. 1 1993, 1891-1896. Varvoglis, A.; Spyroudis, S. Hypervalent iodine chemistry: 25 years of development at the university of Thessaloniki. Synlett 1998, 221-232.
33. Chiba, K.; Toda, M. Diels Alder reaction of quinones generated in situ by electrochemical oxidation in lithium perchloratenitromethane. J. Chem. Soc., Chem. Commun. 1994, 2485-2486. Chiba, K.; Arakawa, T.; Toda, M. Synthesis of euglobal-G3 and G4. J. Chem. Soc., Chem. Commun. 1996, 1763-1764.
34. Chiba, K.; Toda, M. Diels Alder reaction of quinones generated in situ by electrochemical oxidation in lithium perchloratenitromethane. J. Chem. Soc., Chem. Commun. 1994, 2485-2486. Chiba, K.; Arakawa, T.; Toda, M. Synthesis of euglobal-G3 and G4. J. Chem. Soc., Chem. Commun. 1996, 1763-1764.
35. Pelter, A.; Ward, R. S. The production of a novel podophyllotoxin derivative. J. Nat. Prod. 1993, 56, 2204-2206.
36. Hara, H.; Shinoki, H.; Hoshino, O.; Umezawa, B. A synthesis of 3-hydroxyaporphine and homoaporphine. Heterocycles 1983, 20, 2155-2158.
37. Kokil, P. B.; Madhavan Nair, P. Chemistry of trivalent iodine: Part I. Iodonium ylides from phenols. Tetrahedron Lett. 1977, 4113-4116.
38. Prakash, O.; Kumar, D.; Saini, R. K.; Singh, S. P. Hypervalent iodine oxidation of 2-methylquinolones using [hydroxy(tosyloxy)-iodo]benzene - synthesis of 2-methyl-3-iodo-4-phenoxyquinolines via novel monocarbonyl iodonium ylides. Tetrahedron Lett. 1994, 35, 4211-4214. Georgantji, A.; Spyroudis, S. P. From aryliodonioquinoline-8-olates to arylquinolinim-8-olates by a 2 step aryl migration. Tetrahedron Lett. 1995, 36, 443-446.
39. Prakash, O.; Kumar, D.; Saini, R. K.; Singh, S. P. Hypervalent iodine oxidation of 2-methylquinolones using [hydroxy(tosyloxy)-iodo]benzene - synthesis of 2-methyl-3-iodo-4-phenoxyquinolines via novel monocarbonyl iodonium ylides. Tetrahedron Lett. 1994, 35, 4211-4214. Georgantji, A.; Spyroudis, S. P. From aryliodonioquinoline-8-olates to arylquinolinim-8-olates by a 2 step aryl migration. Tetrahedron Lett. 1995, 36, 443-446.
40. Wanzlich, H. W. In Newer Methods of Preparative Organic Chemistry; Academic Press: New York, 1988; pp 139-154.
41. Carlini, R.; Fang, C. L.; Herrington, D.; Higgs, K.; Rodrigo, R.; Taylor, N. Effective regiocontrol in the Diels Alder reactions of ortho-benzoquinone dienophiles: dihydronaphthalenes and naphthofurans from catechols by a one pot process. Aust. J. Chem. 1997, 50, 271-278. Carlini, R.; Higgs, K.; Taylor, N.; Rodrigo, R. Diels Alder adducts of ortho-benzoquinones: rearangements and further transformations. Can. J. Chem. 1997, 50, 2271-278.
42. Carlini, R.; Fang, C. L.; Herrington, D.; Higgs, K.; Rodrigo, R.; Taylor, N. Effective regiocontrol in the Diels Alder reactions of ortho-benzoquinone dienophiles: dihydronaphthalenes and naphthofurans from catechols by a one pot process. Aust. J. Chem. 1997, 50, 271-278. Carlini, R.; Higgs, K.; Taylor, N.; Rodrigo, R. Diels Alder adducts of ortho-benzoquinones: rearangements and further transformations. Can. J. Chem. 1997, 50, 2271-278.
43. 2. J. Chem. Soc., Chem. Commun. 1999, 1207-1208.
44. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-104.
45. http://dtp.nci.nih.gov.
46. Wosikowski, K.; Schuurhuis, D.; Johnson, K.; Paull, KD.; Myers, T. G.; Weinstein, J. N.; Bates, S. E. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 1997, 89, 1505-1515.
47. Houlbrook, S.; Addison, C. M.; Davies, S. L.; Carmichael, J.; Stratford, I. J.; Harris, A. L.; Hickson, I. D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer 1995, 72, 1454-1461.
48. Stratford, I. J.; Stephens, M. A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Rad. Oncol. Biol. Phys. 1989, 16, 973-976.
49. Dickstein, B. M.; Wosikowski, K.; Bates, S. E. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol. 1995, 110, 205-211.
50. Fox, A. R.; Pausacher, K. H. Oxidations with phenyliodosoacetate part VI. The oxidation of some phenols containing electron attracting substituents. J. Chem. Soc. 1957, 295-300.
51. Filmus, J.; Pollack, M. N.; Cailleau, R.; Buick, R. N. MDA 468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGR receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun. 1985, 128, 898-905.
52. King, R. C.; Borello, I.; Bellot, F.; Comoglio, P.; Schlesinger, J. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB2 protein in the mammary tumour cell line SkBr3 EMBO J. 1988, 7, 1647-1651.
53. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.